Benefits of Intensive Pain Control in Early Rheumatoid Arthritis
The study shows a need for more intensive pain control early in RA.
A subset of patients with rheumatoid arthritis (RA) on methotrexate (MTX) therapy were found to have persistent pain despite improvements in Disease Activity Scores in 28 joints (DAS28), suggesting components of RA pain are not mediated by inflammatory processes and may benefit from treatment other than anti-inflammatory agents. These findings were recently published in Arthritis Care & Research.1
Much of the disability associated with RA relates to the pain secondary to inflammatory joint inflammation. Adequate disease control with disease-modifying anti-rheumatic drugs (DMARDs) has been shown to improve measures of pain, especially in early RA. A subset of patients experience residual pain despite early implementation of treat-to-target therapy with adequate control of systemic inflammation.
Researchers utilized data from the Epidemiological Investigation of RA (EIRA), a case-control study analyzing data of adults with newly diagnosed RA at the population level in Sweden. Clinical data including RA disease activity, treatments prescribed, and any disability were pulled from The Swedish Rheumatology Quality Register (SRQ) surveillance system.
Patients with newly diagnosed RA initiated on MTX were asked to participate in both the EIRA and SRQ, with 1 241 patients with visual analog scale (VAS) and DAS28 follow-up data eventually included for data analysis. Significant residual RA pain was defined by VAS pain > 20 mm.
The European League Against Rheumatism (EULAR) response criteria, taking DAS28 and total joint counts 28 (TJC28) into account were used to classify treatment response as "good", "moderate", or "no response". In addition, inflammatory markers including C-reactive protein (CRP) were taken at 3 months post-MTX initiation.
Of these patients, 40% achieved EULAR good response, 38% achieved EULAR moderate response, and 23% achieved any response. After 3 months of DMARD treatment with MTX, 29% of patients who had achieved EULAR good response had residual pain. This is in comparison to the 70% of patients who achieved EULAR moderate response with residual pain at 3 months post-treatment initiation.
"These data show that significant pain after good clinical response is common in early RA and support the need for more intensive pain control early in the disease," the authors stated.
Researchers further found that increased baseline disease activity, as measured by the Health Assessment Questionnaire (HAQ), was predictive of residual pain at 3 months, despite achieving EULAR good treatment response (adjusted odds ratio [OR] 2.2; 95% confidence interval 1.4–3.4] per unit). Reduced baseline systemic inflammation, as measured by erythrocyte sedimentation rate (ESR), was also predictive of residual pain at the same point of time (adjusted OR 0.81 [95% CI 0.70–0.93] per 10-mm increase).
Summary and Clinical Applicability
A subset of patients receiving MTX monotherapy who achieve good EULAR response still have residual pain at 3 months post treatment initiation.
"The observational data from the present and other studies indicate that emphasis should also be laid on better strategies for treatment of concomitant pain during the course of arthritis... [and further] emphasize that the impact on disease activity and pain do not necessarily occur in parallel," the authors concluded.
Limitations and Disclosures
- Inability to control for potential confounders known to influence symptoms of pain in RA, including depression and smoking
- Only patients receiving MTX monotherapy were included in this data analysis, limiting generalizability
Dr Klareskog has received speaking fees from Wyeth, Bristol-Myers Squibb, Merck, Sharp & Dome, AbbVie, and Roche. Dr Lampa has received speaking fees from AbbVie, Merck, Sharp & Dome, Pfizer, UCB Pharma, Novartis, and Roche.
- Altawil R, Saevarsdottir S, Wedrén S, Alfredsson L, Klareskog L, Lampa J. Remaining pain in early rheumatoid arthritis patients treated with methotrexate. Arthritis Care Res (Hoboken). 2016;68(8):1061-8. doi: 10.1002/acr.22790